vs

Side-by-side financial comparison of Stock Yards Bancorp, Inc. (SYBT) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $104.4M, roughly 1.5× Stock Yards Bancorp, Inc.). Stock Yards Bancorp, Inc. runs the higher net margin — 35.1% vs -5.5%, a 40.6% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 11.7%). Stock Yards Bancorp, Inc. produced more free cash flow last quarter ($154.0M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 11.9%).

Community Trust Bancorp is an American regional bank holding company that was founded in 1903 as Pikeville National Bank. The renamed corporation continues to have its headquarters in Pikeville, Kentucky, at the heart of Appalachia. Community Trust Bancorp operates a commercial bank, Community Trust Bank, and a trust company, Community Trust and Investment Company of Lexington.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

SYBT vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.5× larger
TARS
$151.7M
$104.4M
SYBT
Growing faster (revenue YoY)
TARS
TARS
+116.7% gap
TARS
128.4%
11.7%
SYBT
Higher net margin
SYBT
SYBT
40.6% more per $
SYBT
35.1%
-5.5%
TARS
More free cash flow
SYBT
SYBT
$141.0M more FCF
SYBT
$154.0M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
11.9%
SYBT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SYBT
SYBT
TARS
TARS
Revenue
$104.4M
$151.7M
Net Profit
$36.6M
$-8.4M
Gross Margin
Operating Margin
45.9%
-5.3%
Net Margin
35.1%
-5.5%
Revenue YoY
11.7%
128.4%
Net Profit YoY
15.5%
63.8%
EPS (diluted)
$1.24
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SYBT
SYBT
TARS
TARS
Q4 25
$104.4M
$151.7M
Q3 25
$101.5M
$118.7M
Q2 25
$97.8M
$102.7M
Q1 25
$93.5M
$78.3M
Q4 24
$93.5M
$66.4M
Q3 24
$89.8M
$48.1M
Q2 24
$85.7M
$40.8M
Q1 24
$83.3M
$27.6M
Net Profit
SYBT
SYBT
TARS
TARS
Q4 25
$36.6M
$-8.4M
Q3 25
$36.2M
$-12.6M
Q2 25
$34.0M
$-20.3M
Q1 25
$33.3M
$-25.1M
Q4 24
$31.7M
$-23.1M
Q3 24
$29.4M
$-23.4M
Q2 24
$27.6M
$-33.3M
Q1 24
$25.9M
$-35.7M
Operating Margin
SYBT
SYBT
TARS
TARS
Q4 25
45.9%
-5.3%
Q3 25
45.0%
-12.2%
Q2 25
43.9%
-21.6%
Q1 25
44.5%
-33.5%
Q4 24
41.9%
-36.8%
Q3 24
41.2%
-52.3%
Q2 24
41.2%
-81.6%
Q1 24
39.5%
-136.5%
Net Margin
SYBT
SYBT
TARS
TARS
Q4 25
35.1%
-5.5%
Q3 25
35.7%
-10.6%
Q2 25
34.8%
-19.8%
Q1 25
35.6%
-32.1%
Q4 24
33.9%
-34.8%
Q3 24
32.7%
-48.7%
Q2 24
32.2%
-81.6%
Q1 24
31.1%
-129.4%
EPS (diluted)
SYBT
SYBT
TARS
TARS
Q4 25
$1.24
$-0.17
Q3 25
$1.23
$-0.30
Q2 25
$1.15
$-0.48
Q1 25
$1.13
$-0.64
Q4 24
$1.07
$-0.57
Q3 24
$1.00
$-0.61
Q2 24
$0.94
$-0.88
Q1 24
$0.88
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SYBT
SYBT
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$26.8M
$72.4M
Stockholders' EquityBook value
$1.1B
$343.4M
Total Assets
$9.5B
$562.2M
Debt / EquityLower = less leverage
0.02×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SYBT
SYBT
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
SYBT
SYBT
TARS
TARS
Q4 25
$26.8M
$72.4M
Q3 25
$26.8M
$72.3M
Q2 25
$72.1M
Q1 25
$26.8M
$72.0M
Q4 24
$26.8M
$71.8M
Q3 24
$26.8M
$71.7M
Q2 24
$26.8M
$71.6M
Q1 24
$26.8M
$29.9M
Stockholders' Equity
SYBT
SYBT
TARS
TARS
Q4 25
$1.1B
$343.4M
Q3 25
$1.0B
$335.1M
Q2 25
$1.0B
$332.6M
Q1 25
$975.5M
$342.5M
Q4 24
$940.5M
$224.5M
Q3 24
$934.1M
$237.5M
Q2 24
$894.5M
$252.2M
Q1 24
$874.7M
$275.2M
Total Assets
SYBT
SYBT
TARS
TARS
Q4 25
$9.5B
$562.2M
Q3 25
$9.3B
$534.6M
Q2 25
$9.2B
$495.0M
Q1 25
$9.0B
$500.8M
Q4 24
$8.9B
$377.0M
Q3 24
$8.4B
$376.3M
Q2 24
$8.3B
$376.8M
Q1 24
$8.1B
$349.3M
Debt / Equity
SYBT
SYBT
TARS
TARS
Q4 25
0.02×
0.21×
Q3 25
0.03×
0.22×
Q2 25
0.22×
Q1 25
0.03×
0.21×
Q4 24
0.03×
0.32×
Q3 24
0.03×
0.30×
Q2 24
0.03×
0.28×
Q1 24
0.03×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SYBT
SYBT
TARS
TARS
Operating Cash FlowLast quarter
$166.0M
$19.3M
Free Cash FlowOCF − Capex
$154.0M
$13.0M
FCF MarginFCF / Revenue
147.5%
8.6%
Capex IntensityCapex / Revenue
11.5%
4.2%
Cash ConversionOCF / Net Profit
4.54×
TTM Free Cash FlowTrailing 4 quarters
$260.5M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SYBT
SYBT
TARS
TARS
Q4 25
$166.0M
$19.3M
Q3 25
$38.2M
$18.3M
Q2 25
$55.9M
$-29.4M
Q1 25
$19.8M
$-20.7M
Q4 24
$142.9M
$-22.2M
Q3 24
$55.4M
$-8.7M
Q2 24
$51.1M
$-14.4M
Q1 24
$17.4M
$-37.8M
Free Cash Flow
SYBT
SYBT
TARS
TARS
Q4 25
$154.0M
$13.0M
Q3 25
$35.2M
$16.3M
Q2 25
$53.5M
$-30.4M
Q1 25
$17.8M
$-21.2M
Q4 24
$133.0M
$-22.3M
Q3 24
$53.9M
$-8.9M
Q2 24
$47.9M
$-15.4M
Q1 24
$15.6M
$-38.0M
FCF Margin
SYBT
SYBT
TARS
TARS
Q4 25
147.5%
8.6%
Q3 25
34.6%
13.8%
Q2 25
54.7%
-29.6%
Q1 25
19.1%
-27.1%
Q4 24
142.3%
-33.5%
Q3 24
60.0%
-18.6%
Q2 24
55.9%
-37.8%
Q1 24
18.7%
-137.5%
Capex Intensity
SYBT
SYBT
TARS
TARS
Q4 25
11.5%
4.2%
Q3 25
3.0%
1.6%
Q2 25
2.5%
1.0%
Q1 25
2.1%
0.8%
Q4 24
10.5%
0.1%
Q3 24
1.7%
0.6%
Q2 24
3.8%
2.5%
Q1 24
2.2%
0.6%
Cash Conversion
SYBT
SYBT
TARS
TARS
Q4 25
4.54×
Q3 25
1.05×
Q2 25
1.64×
Q1 25
0.59×
Q4 24
4.51×
Q3 24
1.89×
Q2 24
1.85×
Q1 24
0.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons